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Atrial fibrillation (AF) is the most common arrhythmia and
its prevalence and incidence increase with age, but also
with cardiovascular morbidity, such as hypertension, diabe-
tes, vascular and valvular disease and heart failure. Indeed,
in patients with implantable cardioverter defibrillators
(ICD), who usually have one or more of these predisposing
factors, a history of AF was present in 33 % [1]. In this
patient group AF can be symptomatic for example by
causing palpitations, dyspnoea and fatigue, but can also
worsen heart failure and lead to inappropriate ICD
discharges.
The electrophysiological substrate of persistent AF is
heterogeneous, but the fact that the arrhythmia does not
terminate spontaneously, as paroxysmal AF does, and may
require cardioversion, triggers the impression that the sub-
strate is more advanced in this type of AF. This is evidenced
by more left atrial fibrosis, dilated atria and lower intracar-
dial electrogram amplitudes in persistent versus paroxysmal
AF [2, 3].
Despite the fact that pharmacological cardioversion is
recommended as the first-line treatment option in patients
with recent-onset AF [4], electrical cardioversion (ECV) is
highly efficacious in restoring sinus rhythm in patients
with AF, and performed on a daily basis in most hospitals.
Patients with ICDs in this respect form an interesting
subgroup, while they carry their cardioverter subcutaneously
or under the pectoral muscle. Indeed, it was shown in a
population of patients with cardiac resynchronisation therapy
that internal cardioversion was associated with 82 % of resto-
ration of sinus rhythm [5]. Aside from the demonstration of
feasibility, the efficacy seems somewhat lower than conven-
tional, external ECV and the question arises whether internal
defibrillation should be implemented into clinical practice.
In this issue of the Netherlands Heart Journal Limantoro
et al. describe the efficacy of internal cardioversion using the
ICD in all-comers with persistent AF [6]. They show a disap-
pointingly low cardioversion rate of 33 % among the 27
patients with persistent AF in whom internal cardioversion
was attempted. Patients with failed internal cardioversion
subsequently underwent external electrical cardioversion,
which was effective in all of the patients.
Interestingly, looking further into the characteristics of the
patients who failed internal cardioversion, Limantoro et al.
report that those patients had significantly larger left atrial
volumes (146±44 ml vs. 99±36 ml), a longer total AF history
(40 (5–75) vs. 2 (0–17) months) and shorter right atrial cycle
length (169 (152–183) ms vs. 227 (186–255) ms), as recorded
from the atrial lead of the ICD. The investigators suggest that
the atrial substrate, as clinically assessed with these parame-
ters, negatively affects the atrial defibrillation threshold for
internal cardioversion of AF, which is supported by the even
lower efficacy of 10 % of subsequent internally delivered
shocks. Furthermore, they describe that three out of four
(75 %) patients with a dual-coil ICD had successful internal
cardioversion. On the other hand, only 28 % of 23 patients
with a single-coil ICD were cardioverted internally, demon-
strating that internal cardioversion was particularly ineffective
in this group. Therefore, they emphasise the importance of
patient selection: Patients with a short history of AF and small
atria may be suitable for internal cardioversion, but patients
Editorial comment to: Limantoro et al. ‘Low efficacy of cardioversion of
persistent atrial fibrillation with the implantable cardioverter defibrillator’
doi:10.1007/s12471-013-0474-z
W. R. Berger : R. E. Knops : J. R. de Groot
Heart Center, Department of Cardiology, Academic Medical Center,
Amsterdam, the Netherlands
J. R. de Groot (*)
Heart Center, Department of Cardiology, Academisch Medisch
Centrum, Meibergdreef 9, 1100 DD Amsterdam, the Netherlands
e-mail: j.r.degroot@amc.uva.nl
Neth Heart J (2013) 21:545–547
DOI 10.1007/s12471-013-0486-8
with more structurally remodelled atria should rather directly
undergo external cardioversion to achieve sinus rhythm. As of
today, we do not know whether the three parameters men-
tioned above are sufficient to determine the extent of atrial
substrate remodelling in these patients. It can be hypothesised
that the amount of fibrosis, which is very hard to determine
echocardiographically (although atrial fibrosis is associated
with left atrial size), may have an important contribution to
the atrial defibrillation threshold. Potentially, there is an
unrecognised group of patients with remodelled atria who
are not detected with these three parameters and in whom
internal cardioversion may be evenly unsuccessful.
It is tempting to seek the characteristics of the atrial sub-
strate as a determinant of internal cardioversion success, but
against the background of the data that Limantaro et al. de-
scribe, the most important question is why internal cardiover-
sion should be considered in ICD patients at all.
One reason could be that external cardioversion could dam-
age the device. There are indeed older case reports on broken
implanted rhythm devices after direct current shocks requiring
replacement of the device [7]. Generally, it is advised to place
the paddles of the external defibrillator in an anteroposterior
manner to avoid current flow through the device causing
device and/or electrode dysfunction. With external cardiover-
sion being performed almost daily in most cardiac care units,
shock paddles could theoretically be misplaced and cause
damage to the ICD. However, Manegold et al. [8] showed that
using the appropriate (antero-posterior) paddle position, exter-
nal cardioversion for AF is safe and effective in patients with
implanted rhythm devices and no device or lead dysfunction
was reported in any of their patients.
Another advantage could be that less shock energy is
required with internal cardioversion as compared with ECV,
but the clinical interpretation thereof is unclear. It seems
simple logic that more shocks are worse than fewer, and that
the first shock should be aimed at restoring sinus rhythm in as
many patients as possible.
Other sources of potential adverse effects associated with
cardioversion include the risk of thromboembolic complica-
tions, for which the use of anticoagulants is clearly defined in
the guidelines [4] and complications associated with the use of
general anaesthesia. These factors, however, are present to the
same extent in patients being cardioverted internally as exter-
nally. The use of general anaesthesia, and therefore the pres-
ence of an anaesthesiologist at the site, as described by
Limantaro et al., and conform the current clinical practice in
most centres, importantly limits the potential benefits of inter-
nal cardioversion. Additionally, for internal cardioversion an
ICD technician is needed to program the ICD and apply the
internal shock. The requirement of the presence of several
professionals in performing the procedure can be a logistic
disadvantage of internal cardioversion and result in signifi-
cantly higher costs.
Finally, as Limantoro et al. discuss, extra shocks performed
with an implantable cardioverter defibrillator may have a neg-
ative impact on battery lifetime. Battery depletion is the major
cause of ICD replacement, which is associated with higher
risks for the patient [9]. Moreover, saving battery lifetime will
reduce the number of ICD generator changes, maybe not on the
level of the individual patient, but certainly on a population
level. Consequently, saving battery lifetime is expected to
reduce complications and costs. This is especially true in pa-
tients with frequent recurrences of AF, something that is not
uncommon in persistent AF. Hence, battery depletion has to be
taken into account when considering internal cardioversion.
Taking the above argumentation into account Limantoro
et al. raise the justified question if internal cardioversion
should be the preferred treatment of choice in patients with
an ICD. As a conclusion from the disappointingly low effica-
cy rate for internal cardioversion, they answer that question
with ‘no’ and they have indeed discontinued this practice in
their own hospital. Internal cardioversion seems to have no
significant advantages over external cardioversion. Determin-
ing the atrial substrate of AF, although scientifically very
interesting for a better understanding the disease, may there-
fore be futile when choosing the cardioversion strategy in
patients with an ICD and persistent AF. It may be, however,
of importance to find parameters that can determine patients in
whom atrial remodelling is advanced and who will experience
frequent recurrences, despite cardioversion. Since ECV was
eventually successful in all the patients in the study by
Limantoro et al., this determinationmay be relevant for patient
prognosis, but not for cardioversion success.
The goal of cardioversion in patients with AF is restoration
of sinus rhythm, while applying the least number of shocks.
Apart from the patients with recent-onset AF, in whom phar-
macological cardioversion is applied, the results of the study
by Limantoro et al. point us in the direction of applying
external cardioversion as treatment of choice for persistent
AF, whether the patient carries an ICD or not.
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